Alumis’s lead drug candidate blocks TYK2, an inflammation target that’s already addressed by Sotyktu, a Bristol Myers Squibb drug approved for plaque psoriasis. Alumis plans to begin two Phase 3 tests in this indication later this year. The post Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials appeared first on MedCity News.

View Entire Post